KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Receivables (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Receivables data on record, last reported at $200000.0 in Q3 2025.

  • For Q3 2025, Receivables changed N/A year-over-year to $200000.0; the TTM value through Sep 2025 reached $200000.0, changed N/A, while the annual FY2024 figure was $1.1 million, 35.48% down from the prior year.
  • Receivables reached $200000.0 in Q3 2025 per NKTR's latest filing, down from $1.1 million in the prior quarter.
  • Across five years, Receivables topped out at $30.2 million in Q1 2022 and bottomed at $200000.0 in Q3 2025.
  • Average Receivables over 5 years is $11.5 million, with a median of $5.1 million recorded in 2022.
  • Peak YoY movement for Receivables: plummeted 90.09% in 2023, then rose 20.77% in 2024.
  • A 5-year view of Receivables shows it stood at $23.9 million in 2021, then plummeted by 72.04% to $6.7 million in 2022, then crashed by 74.48% to $1.7 million in 2023, then plummeted by 35.48% to $1.1 million in 2024, then crashed by 81.82% to $200000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $200000.0 in Q3 2025, $1.1 million in Q4 2024, and $1.2 million in Q2 2024.